ÂÜÀòÂÒÂ×

Suji Venugopal-Prasad has served as Vice President, Clinical Operations since July 2021. She has over 20 years of clinical operations experience working on oncology and autoimmune drug development programs. Her breadth of experience spans pre-IND planning through NDA submissions in emerging and established pharmaceutical companies. Most recently as the Executive Director and Head of Clinical Operations at ChemoCentryx, she oversaw clinical trial strategy and execution of studies in autoimmune, oncology, renal, and dermatology indications including supporting an NDA submission for the ANCA associated vasculitis study with avacopan, a C5a receptor inhibitor. Prior to that as the Head of Clinical Operations at Cleave Biosciences, she oversaw the management of clinical trials with the VCP/p97 inhibitor CB-5083, in multiple myeloma and solid tumors. Previously at Onyx/Amgen she led the successful execution of the pivotal study with Kyprolis (carfilzomib), a selective proteasome inhibitor, and supported FDA and other country submissions that led to global approvals. From 2003 – 2011 she held leadership roles of increasing responsibilities and managed first-in-human to global phase 3 clinical trials in various solid tumors and hematologic cancers at Scios (J&J), Nuvelo, and Novacea. Suji holds a Bachelor of Science from Madras University, and a Master of Science from Bharathiyar University, India.